BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D, van der Sande F, Popa GT, Morosanu C, Covic A. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant 2019;34:923-33. [PMID: 30879070 DOI: 10.1093/ndt/gfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Charles PY, Le Meur Y, Tanquerel T, Galinat H. Vitamin K antagonist has a higher impact than heparin in preventing circuit clotting in chronic haemodialysis patients. Clin Kidney J 2020;13:647-53. [PMID: 32905339 DOI: 10.1093/ckj/sfz131] [Reference Citation Analysis]
2 Park S, Kim Y, Jo HA, Lee S, Kim MS, Yang BR, Lee J, Han SS, Lee H, Lee JP, Joo KW, Lim CS, Kim YS, Kim DK. Clinical outcomes of prolonged dual antiplatelet therapy after coronary drug-eluting stent implantation in dialysis patients. Clin Kidney J 2020;13:803-12. [PMID: 33125004 DOI: 10.1093/ckj/sfaa037] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
3 Derebail VK, Rheault MN, Kerlin BA. Role of direct oral anticoagulants in patients with kidney disease. Kidney Int 2020;97:664-75. [PMID: 32107019 DOI: 10.1016/j.kint.2019.11.027] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
4 Hau HM, Eckert M, Laudi S, Völker MT, Stehr S, Rademacher S, Seehofer D, Sucher R, Piegeler T, Jahn N. Predictive Value of HAS-BLED Score Regarding Bleeding Events and Graft Survival following Renal Transplantation. JCM 2022;11:4025. [DOI: 10.3390/jcm11144025] [Reference Citation Analysis]
5 Burlacu A, McCullough PA, Covic A. Cardionephrology from the point of view of the cardiologist: no more agree to disagree-getting to 'yes' for every patient. Clin Kidney J 2021;14:1995-9. [PMID: 34476086 DOI: 10.1093/ckj/sfab092] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Cases A, Gomez P, Broseta JJ, Perez Bernat E, Arjona Barrionuevo JD, Portolés JM, Gorriz JL. Non-valvular Atrial Fibrillation in CKD: Role of Vitamin K Antagonists and Direct Oral Anticoagulants. A Narrative Review. Front Med (Lausanne) 2021;8:654620. [PMID: 34604247 DOI: 10.3389/fmed.2021.654620] [Reference Citation Analysis]
7 Baliou S, Adamaki M, Ioannou P, Pappa A, Panayiotidis MI, Spandidos DA, Christodoulou I, Kyriakopoulos AM, Zoumpourlis V. Protective role of taurine against oxidative stress (Review). Mol Med Rep 2021;24:605. [PMID: 34184084 DOI: 10.3892/mmr.2021.12242] [Reference Citation Analysis]
8 Khedraki R, Dhar J, Baldwin WM. Platelets: Mechanistic and Diagnostic Significance in Transplantation. Curr Transpl Rep 2020;7:124-30. [DOI: 10.1007/s40472-020-00272-4] [Reference Citation Analysis]
9 Burlacu A, Iftene A, Busoiu E, Cogean D, Covic A. Challenging the supremacy of evidence-based medicine through artificial intelligence: the time has come for a change of paradigms. Nephrol Dial Transplant 2020;35:191-4. [PMID: 31697377 DOI: 10.1093/ndt/gfz203] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
10 Laville SM, Lambert O, Hamroun A, Metzger M, Jacquelinet C, Laville M, Frimat L, Fouque D, Combe C, Ayav C, Pecoits-Filho R, Stengel B, Massy ZA, Liabeuf S; CKD-REIN Study Collaborators. Consequences of oral antithrombotic use in patients with chronic kidney disease. Clin Transl Sci 2021. [PMID: 34080321 DOI: 10.1111/cts.13084] [Reference Citation Analysis]
11 Canney M, Sood MM, Hundemer GL. Reducing the risk of atrial fibrillation in ESKD: is the devil in the dialysis? Nephrol Dial Transplant 2021;36:1963-4. [PMID: 33751116 DOI: 10.1093/ndt/gfab063] [Reference Citation Analysis]
12 Ponchia PI, Ahmed R, Farag M, Alkhalil M. Antiplatelet Therapy in End-stage Renal Disease Patients on Maintenance Dialysis: a State-of-the-art Review. Cardiovasc Drugs Ther 2022. [PMID: 35867319 DOI: 10.1007/s10557-022-07366-4] [Reference Citation Analysis]
13 Parker K, Wong J. Is polypharmacy an increasing burden in chronic kidney disease? The German experience. Clin Kidney J 2019;12:659-62. [PMID: 31584570 DOI: 10.1093/ckj/sfz072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Bover J, Ureña-Torres P, Mateu S, DaSilva I, Gràcia S, Sánchez-Baya M, Arana C, Fayos L, Guirado L, Cozzolino M. Evidence in chronic kidney disease-mineral and bone disorder guidelines: is it time to treat or time to wait? Clin Kidney J 2020;13:513-21. [PMID: 32905295 DOI: 10.1093/ckj/sfz187] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]